RT Journal Article SR Electronic T1 Statin use is associated with reduced mortality after respiratory viral infection JF ERJ Open Research JO erjor FD European Respiratory Society SP 00365-2020 DO 10.1183/23120541.00365-2020 A1 Juan Antonio Franco-Peláez A1 Laura Esteban-Lucia A1 María de los Ángeles Zambrano Chacón A1 Ana María Pello-Lázaro A1 Ana María Venegas Rodriguez A1 Luis Nieto Roca A1 Camila Sofia García-Talavera A1 Andrea Kallmeyer Mayor A1 Felipe Villar Alvarez A1 Ricardo Fernandez Roblas A1 Oscar Gonzalez-Lorenzo A1 José Tuñón A1 Borja Ibañez A1 Alvaro Aceña YR 2020 UL http://openres.ersjournals.com/content/early/2020/11/12/23120541.00365-2020.abstract AB Background Several studies suggest that statins, besides reducing cardiovascular disease, have anti-inflammatory properties which might provide a benefit in downregulating the immune response after a respiratory viral infection (RVI) and, hence, decreasing subsequent complications. We aim to analyse the effect of statins on mortality after RVI.Methods Single-center, observational and retrospective study including all adult patients with a RVI confirmed by PCR tests from October 2nd, 2017 to May 20th, 2018. Patients were divided between statins and non-statins users and followed-up for 1 year, recording all causes of death. In order to analyse the effect of statin treatment on mortality after RVI we planned two different approaches, a multivariate Cox regression model with the overall population and a univariate Cox model with a propensity-score matched population.Results We included 448 patients, of which 154 (34.4%) were under statin treatment. They had worse clinical profile (older population with more comorbidities). During the 1-year follow-up, 67 patients died, 17 (11.0%) in the statin group, and 50 (17.1%) in the non-statin group. At Cox multivariate analysis, statins were associated with mortality benefit (HR=0.47, 95% CI (0.26–0.83); p=0.01). In matched population (101 statins users and 101 non-statins users) statins also remained associated with mortality benefit (HR=0.32, 95% CI (0.14–0.72); p=0.006). Differences were mainly driven by non-cardiovascular mortality (HR 0.31, 95% CI (0.13–0.73); p=0.004).Conclusions Chronic statin treatment was associated with reduced 1-year mortality in patients with laboratory-confirmed RVI. Further studies are needed to determine the exact role of statin therapy after RVI.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Franco Peláez has nothing to disclose.Conflict of interest: Dr. Esteban Lucía has nothing to disclose.Conflict of interest: Dr. Zambrano Chacón has nothing to disclose.Conflict of interest: Dr. Pello Lázaro has nothing to disclose.Conflict of interest: Dr. Venegas Rodriguez has nothing to disclose.Conflict of interest: Dr. Nieto Roca has nothing to disclose.Conflict of interest: Dr. García Talavera has nothing to disclose.Conflict of interest: Dr. Kallmeyer Mayor has nothing to disclose.Conflict of interest: Dr. Villar Alvarez has nothing to disclose.Conflict of interest: Dr. Fernández Roblas has nothing to disclose.Conflict of interest: Dr. González Lorenzo has nothing to disclose.Conflict of interest: Dr. Tuñon has nothing to disclose.Conflict of interest: Dr. Ibañez has nothing to disclose.Conflict of interest: Dr. Aceña Navarro has nothing to disclose.